Delayed
Deutsche Boerse AG
14:29:01 03/06/2024 BST
|
5-day change
|
1st Jan Change
|
1.32
EUR
|
-6.38%
|
|
-2.94%
|
-49.23%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
18,711
|
64,649
|
56,686
|
57,119
|
35,947
|
23,878
|
-
|
-
|
Enterprise Value (EV)
1 |
18,402
|
62,115
|
53,714
|
52,363
|
33,930
|
20,839
|
21,502
|
21,923
|
P/E ratio
|
-24.9
x
|
-23.4
x
|
-59.1
x
|
-
|
-
|
-6.83
x
|
-9.21
x
|
-11.3
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
24.1
x
|
40.5
x
|
14.1
x
|
39.3
x
|
23.9
x
|
11.2
x
|
7.47
x
|
5.77
x
|
EV / Revenue
|
23.7
x
|
38.9
x
|
13.3
x
|
36
x
|
22.6
x
|
9.79
x
|
6.72
x
|
5.3
x
|
EV / EBITDA
|
-23.5
x
|
-41.7
x
|
-127
x
|
-21.7
x
|
-15.7
x
|
-15.3
x
|
-21.3
x
|
-24.9
x
|
EV / FCF
|
-9.3
x
|
-30.5
x
|
-38
x
|
-24.1
x
|
-12
x
|
-10.3
x
|
-25.3
x
|
-15.7
x
|
FCF Yield
|
-10.8%
|
-3.28%
|
-2.63%
|
-4.14%
|
-8.35%
|
-9.7%
|
-3.96%
|
-6.36%
|
Price to Book
|
6.26
x
|
7.14
x
|
5.17
x
|
-
|
-
|
1.5
x
|
1.65
x
|
1.57
x
|
Nbr of stocks (in thousands)
|
784,147
|
872,496
|
910,757
|
982,872
|
985,011
|
984,908
|
-
|
-
|
Reference price
2 |
23.86
|
47.81
|
47.26
|
42.83
|
17.67
|
10.82
|
10.82
|
10.82
|
Announcement Date
|
02/03/20
|
26/02/21
|
25/02/22
|
27/02/23
|
23/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
775.1
|
1,595
|
4,025
|
1,453
|
1,503
|
2,129
|
3,198
|
4,135
|
EBITDA
1 |
-783.5
|
-1,490
|
-422
|
-2,417
|
-2,168
|
-1,360
|
-1,008
|
-880
|
EBIT
1 |
-747.3
|
-1,636
|
-558.3
|
-2,666
|
-2,457
|
-1,581
|
-868.7
|
-16.98
|
Operating Margin
|
-96.41%
|
-102.59%
|
-13.87%
|
-183.41%
|
-163.55%
|
-74.27%
|
-27.16%
|
-0.41%
|
Earnings before Tax (EBT)
1 |
-763.1
|
-1,672
|
-595
|
-2,677
|
-2,492
|
-1,538
|
-767.7
|
-43.62
|
Net income
1 |
-747.4
|
-1,669
|
-720.9
|
-2,388
|
-2,283
|
-1,433
|
-717.5
|
-85.17
|
Net margin
|
-96.43%
|
-104.62%
|
-17.91%
|
-164.3%
|
-151.97%
|
-67.29%
|
-22.44%
|
-2.06%
|
EPS
2 |
-0.9600
|
-2.040
|
-0.8000
|
-
|
-
|
-1.583
|
-1.175
|
-0.9566
|
Free Cash Flow
1 |
-1,979
|
-2,037
|
-1,414
|
-2,170
|
-2,833
|
-2,021
|
-850.5
|
-399
|
FCF margin
|
-255.28%
|
-127.71%
|
-35.14%
|
-149.31%
|
-188.58%
|
-94.92%
|
-26.6%
|
-9.65%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
02/03/20
|
26/02/21
|
25/02/22
|
27/02/23
|
23/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
309
|
2,534
|
2,972
|
4,756
|
2,017
|
3,039
|
2,377
|
1,956
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-1,979
|
-2,037
|
-1,414
|
-2,170
|
-2,833
|
-2,014
|
-851
|
-399
|
ROE (net income / shareholders' equity)
|
-23.6%
|
-37.7%
|
-10.4%
|
-32.7%
|
-27.3%
|
-23.1%
|
-11.5%
|
-0.15%
|
ROA (Net income/ Total Assets)
|
-17.1%
|
-26.8%
|
-9.24%
|
-
|
-18.8%
|
-14.7%
|
-6.78%
|
-0.61%
|
Assets
1 |
4,360
|
6,228
|
7,802
|
-
|
12,138
|
9,766
|
10,589
|
13,863
|
Book Value Per Share
2 |
3.810
|
6.690
|
9.150
|
-
|
-
|
7.200
|
6.550
|
6.890
|
Cash Flow per Share
2 |
-0.9100
|
-1.780
|
-0.7200
|
-
|
-
|
-1.220
|
-0.5700
|
-
|
Capex
1 |
792
|
580
|
772
|
394
|
828
|
610
|
490
|
373
|
Capex / Sales
|
102.13%
|
36.4%
|
19.19%
|
27.1%
|
55.14%
|
28.63%
|
15.31%
|
9.02%
|
Announcement Date
|
02/03/20
|
26/02/21
|
25/02/22
|
27/02/23
|
23/02/24
|
-
|
-
|
-
|
Last Close Price
10.82
CNY Average target price
22.86
CNY Spread / Average Target +111.32% Consensus |
1st Jan change
|
Capi.
|
---|
| -1.85% | 89.87B | | -1.05% | 37.57B | | -11.76% | 32.75B | | +61.85% | 26.47B | | -21.19% | 14.25B | | -6.55% | 12.99B | | -11.42% | 11.93B | | -47.67% | 10.84B | | +5.99% | 9.11B |
Biopharmaceuticals
|